Stipple Bio
Updated: May 08, 2026
CEO - Jeff Landau
Country: USA | Funding: $121.5M (+)
Founded: 2022
Website: https://www.stipple.bio
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
Founded: 2022
Website: https://www.stipple.bio
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
